一品紅(300723.SZ):丙氨酰谷氨醯胺注射液獲批上市
格隆匯6月20日丨一品紅(300723.SZ)公佈,公司全資子公司廣州一品紅製藥有限公司於近日收到國家藥品監督管理局核准簽發的關於丙氨酰谷氨醯胺注射液的《藥品註冊證書》。
本產品適應症:作為臨牀營養方案的一部分,適用於高分解和/或高代謝狀態的患者。應與腸外營養或腸內營養或兩者聯合營養同時使用。
谷氨醯胺(GLN)被證實是機體內快速增長細胞的能量來源,如腸粘膜上皮細胞和免疫細胞等,可減少腸粘膜萎縮,維護腸屏障功能,繼而減少腸道細菌及內毒素移位,以及改善機體免疫抑制狀態等作用。此外,谷氨醯胺也可促進蛋白質合成,減輕氧化應激損害,調控炎性介質的產生和釋放。谷氨醯胺先後獲得《ESPEN指南:急慢性胰腺炎的臨牀營養(2020)》、《結直腸癌患者的營養治療專家共識(2022)》、《血液系統腫瘤患者的營養治療專家共識(2022)》、《胃癌患者的營養治療專家共識(2023)》等權威指南推薦。
丙氨酰谷氨醯胺注射液屬於國家醫保乙類產品。公司獲批的丙氨酰谷氨醯胺注射液是以化學藥品4類申報註冊,視同通過仿製藥一致性評價。據米內網數據統計,丙氨酰谷氨醯胺2022年在國內城市公立醫院、縣級公立醫院銷售金額為184,980萬元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.